|
1
|
Su Y, Wang Y, Zhou H, Lei L and Xu L:
MicroRNA-152 targets ADAM17 to suppress NSCLC progression. FEBS
Lett. 588:1983–1988. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bahce I, Yaqub M, Smit EF, Lammertsma AA,
van Dongen GA and Hendrikse NH: Personalizing NSCLC therapy by
chara-cterizing tumors using TKI-PET and immuno-PET. Lung Cancer.
107:1–13. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rotow J and Bivona TG: Understanding and
targeting resistance mechanisms in NSCLC. Nat Rev Cancer.
17:637–658. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sanaei S, Hashemi M, Rezaei M, Hashemi SM,
Bahari G and Ghavami S: Evaluation of the pri-miR-34b/c rs4938723
polymorphism and its association with breast cancer risk. Biomed
Rep. 5:125–129. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li H, Li X, Ge X, Jia L, Zhang Z, Fang R,
Yang J, Liu J, Peng S, Zhou M, et al: MiR-34b-3 and miR-449a
inhibit malignant progression of nasopharyngeal carcinoma by
targeting lactate dehydrogenase A. Oncotarget. 7:54838–54851.
2016.PubMed/NCBI
|
|
6
|
Hashemi M, Danesh H, Bizhani F, Narouie B,
Sotoudeh M, Nouralizadeh A, Sharifiaghdas F, Bahari G and Taheri M:
Pri-miR-34b/c rs4938723 polymorphism increased the risk of prostate
cancer. Cancer Biomark. 18:155–159. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Passaro A, Guerini-Rocco E, Pochesci A,
Vacirca D, Spitaleri G, Catania CM, Rappa A, Barberis M and de
Marinis F: Targeting EGFR T790M mutation in NSCLC: From biology to
evaluation and treatment. Pharmacol Res. 117:406–415. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Comel A, Sorrentino G, Capaci V and Del
Sal G: The cytoplasmic side of p53's oncosuppressive activities.
FEBS Lett. 588:2600–2609. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Edwards T, Al-Najjar H, Crosbie P, Martin
J, Chaturvedi A, Evison M and Booton R: 89P: Investigating the
potential utility of the alternative IASLC nodal staging
classification in NSCLC. J Thorac Oncol. 11 (Suppl):S94–S95. 2016.
View Article : Google Scholar
|
|
10
|
Yang X and Lin D: Changes of 2015 WHO
Histological Classification of Lung Cancer and the clinical
significance. Zhongguo Fei Ai Za Zhi. 19:332–336. 2016.(In
Chinese). PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma ZL, Hou PP, Li YL, Wang DT, Yuan TW,
Wei JL, Zhao BT, Lou JT, Zhao XT, Jin Y, et al: MicroRNA-34a
inhibits the proliferation and promotes the apoptosis of non-small
cell lung cancer H1299 cell line by targeting TGFβR2. Tumour Biol.
36:2481–2490. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang R, Chen XF and Shu YQ: Prediction of
non-small cell lung cancer metastasis-associated microRNAs using
bioinformatics. Am J Cancer Res. 5:32–51. 2014.PubMed/NCBI
|
|
15
|
Hu Z, Hou D, Wang X, You Z and Cao X:
TSPAN12 is overexpressed in NSCLC via p53 inhibition and promotes
NSCLC cell growth in vitro and in vivo. Onco Targets Ther.
11:1095–1103. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin X, Xu XY, Chen QS and Huang C:
Clinical significance of microRNA-34a in esophageal squamous cell
carcinoma. Genet Mol Res. 14:17684–17691. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen LL, Shen Y, Zhang JB, Wang S, Jiang
T, Zheng MQ, Zheng ZJ and Chen CX: Association between
polymorphisms in the promoter region of pri-miR-34b/c and risk of
hepatocellular carcinoma. Genet Mol Res. 15:152016. View Article : Google Scholar
|
|
18
|
Tian Q, Jia J, Ling S, Liu Y, Yang S and
Shao Z: A causal role for circulating miR-34b in osteosarcoma. Eur
J Surg Oncol. 40:67–72. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hu L, Ai J, Long H, Liu W, Wang X, Zuo Y,
Li Y, Wu Q and Deng Y: Integrative microRNA and gene profiling data
analysis reveals novel biomarkers and mechanisms for lung cancer.
Oncotarget. 7:8441–8454. 2016.PubMed/NCBI
|
|
20
|
Halvorsen AR, Bjaanæs M, LeBlanc M, Holm
AM, Bolstad N, Rubio L, Peñalver JC, Cervera J, Mojarrieta JC,
López-Guerrero JA, et al: A unique set of 6 circulating microRNAs
for early detection of non-small cell lung cancer. Oncotarget.
7:37250–37259. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Balça-Silva J, Sousa Neves S, Gonçalves
AC, Abrantes AM, Casalta-Lopes J, Botelho MF, Sarmento-Ribeiro AB
and Silva HC: Effect of miR-34b overexpression on the
radiosensitivity of non-small cell lung cancer cell lines.
Anticancer Res. 32:1603–1609. 2012.PubMed/NCBI
|
|
22
|
Kerr KM and López-Ríos F: Precision
medicine in NSCLC and pathology: how does ALK fit in the pathway?
Ann Oncol. 27:16–24. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cortez MA, Ivan C, Valdecanas D, Wang X,
Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, et al:
PDL1 regulation by p53 via miR-34. J Natl Cancer Inst.
108:v3032015.
|
|
24
|
Wang Z, Chen Z, Gao Y, Li N, Li B, Tan F,
Tan X, Lu N, Sun Y, Sun J, et al: DNA hypermethylation of
microRNA-34b/c has prognostic value for stage I non-small cell lung
cancer. Cancer Biol Ther. 11:490–496. 2011. View Article : Google Scholar : PubMed/NCBI
|
